Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 4, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	7,944	6,083	4,882	7,694	5,659	5,765
Market Cap Growth	19.96%	24.59%	-36.54%	35.96%	-1.84%	122.48%
Enterprise Value	8,552	6,951	5,929	8,940	5,722	5,817
Last Close Price	66.20	47.81	36.96	56.90	40.21	42.71
PE Ratio	14.38	13.70	17.34	38.06	14.05	44.66
Forward PE	9.25	10.38	9.77	21.92	17.89	25.20
PS Ratio	6.50	5.99	5.89	11.66	12.76	21.54
PB Ratio	15.40	16.72	58.26	45.31	28.73	38.17
P/TBV Ratio	-	-	-	-	28.73	38.17
P/FCF Ratio	-	12.99	13.08	32.70	18.99	108.87
P/OCF Ratio	-	12.70	12.57	32.04	18.90	103.95
PEG Ratio	-	0.41	0.41	0.41	0.46	0.55
EV/Sales Ratio	6.88	6.85	7.15	13.54	12.91	21.74
EV/EBITDA Ratio	10.51	11.09	14.22	26.60	20.63	39.89
EV/EBIT Ratio	11.60	12.61	17.43	30.89	20.74	40.33
EV/FCF Ratio	-	14.84	15.88	37.99	19.20	109.86
Debt / Equity Ratio	3.00	4.22	18.27	9.07	4.47	2.66
Debt / EBITDA Ratio	1.85	2.42	3.59	4.54	3.15	2.71
Debt / FCF Ratio	-	3.28	4.10	6.55	2.95	7.59
Asset Turnover	0.57	0.54	0.46	0.45	0.53	0.47
Inventory Turnover	1.71	1.77	2.36	2.67	2.04	1.72
Quick Ratio	1.25	6.50	5.07	4.54	7.10	1.11
Current Ratio	1.59	7.80	6.64	5.65	7.91	1.32
Return on Equity (ROE)	124.50%	198.42%	222.07%	110.23%	231.44%	106.33%
Return on Assets (ROA)	21.24%	18.16%	11.89%	12.28%	20.47%	15.74%
Return on Capital (ROIC)	23.03%	19.61%	12.78%	12.98%	21.16%	17.11%
Return on Capital Employed (ROCE)	53.30%	28.70%	21.00%	16.90%	27.90%	91.00%
Earnings Yield	7.69%	7.30%	5.77%	2.63%	7.12%	2.24%
FCF Yield	-	7.70%	7.65%	3.06%	5.27%	0.92%
Buyback Yield / Dilution	3.26%	3.56%	4.56%	4.21%	-3.77%	1.99%

Updated Nov 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q